“For many cell-based therapies, progress comes from connecting the right pieces at the right moment,” Klein said. “When ...
– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...
The Science Advances publication details Cellgorithm™, a CRISPR-based technology that gives researchers greater control over gene activity and sets the stage for future applications in stem cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results